Hormone replacement therapy (HRT) works by supplying your body with estrogen, and sometimes progesterone, to replace what your ovaries stop producing during menopause. These supplemental hormones enter your cells, bind to specific receptors, and switch genes on or off to restore functions that decline when natural hormone levels drop. The result is relief from hot flashes, protection against bone loss, and a range of other effects that ripple through nearly every organ system.
What Happens Inside Your Cells
Whether you take estrogen as a pill, patch, or gel, the hormone molecules travel through your bloodstream and enter cells throughout your body. Once inside a cell, estrogen binds to estrogen receptors in the cytoplasm, the fluid-filled space surrounding the nucleus. This binding triggers a shape change in the receptor, causing two receptor molecules to pair up. The paired complex then moves into the nucleus, where it attaches to specific stretches of DNA and either activates or silences particular genes.
This is the classical “genomic” pathway, and it’s how estrogen controls processes like bone remodeling, blood vessel flexibility, and the growth of uterine lining tissue. But estrogen also has faster, “non-genomic” effects. Some receptors sit on the outer surface of cells and can influence ion channels and chemical signaling within seconds, essentially acting like a neurotransmitter. This dual mechanism, one slow and gene-based, one fast and electrical, helps explain why estrogen affects such a wide range of tissues.
Why Hot Flashes Stop
Hot flashes happen because falling estrogen levels disrupt your brain’s internal thermostat. The hypothalamus, the region responsible for maintaining stable body temperature, is packed with estrogen receptors, particularly in areas that detect warmth and trigger sweating or flushing. When estrogen drops, these heat-sensitive neurons become hyperactive, misreading normal body temperature as too high and launching a cooling response: blood vessels dilate, skin flushes, and sweat glands fire.
HRT restores estrogen signaling to those neurons, recalibrating the thermostat. Most women notice a meaningful reduction in hot flashes within about six to eight weeks of starting treatment, though some respond faster. Studies show that HRT reduces both the frequency and intensity of hot flashes by close to 90%.
Why Progesterone Is Often Included
Estrogen on its own stimulates the uterine lining to grow. Before menopause, your body balances this with progesterone produced after ovulation each month, which stops the lining from thickening unchecked and triggers a period. Without that counterbalance, estrogen-only therapy can cause the lining to proliferate abnormally, raising the risk of endometrial hyperplasia and, over time, endometrial cancer.
If you still have your uterus, HRT will include a progestogen (either natural progesterone or a synthetic version) to prevent that overgrowth. It can be taken daily alongside estrogen (continuous combined therapy) or for part of each month (sequential therapy). Women who have had a hysterectomy can safely take estrogen alone, since there’s no uterine lining to protect.
How Different Delivery Methods Compare
The route estrogen takes into your body matters more than you might expect. Oral tablets are swallowed and absorbed through the gut, which means they pass through the liver before reaching the rest of your body. This “first pass” through the liver increases the production of clotting factors, which is the main reason oral estrogen carries a slightly higher risk of blood clots and stroke. A large case-control study found oral estrogen users had a 28% higher rate of stroke compared to non-users.
Transdermal options (patches, gels, and sprays) deliver estrogen directly through the skin into the bloodstream, bypassing the liver entirely. The result is a lower effective dose, clotting factor levels that stay closer to normal, and a hormone ratio (estradiol to estrone) more similar to what premenopausal ovaries produce. In the same study, transdermal estrogen showed no increase in stroke risk whatsoever, with a rate essentially identical to women not using HRT. When the two routes were compared head to head, transdermal users had a 26% lower stroke risk than oral users. Low-dose patches in particular showed no elevated risk, while high-dose patches did, reinforcing that both the route and the dose matter.
Effects on Bone
Bone is living tissue that constantly breaks down and rebuilds. Estrogen slows the breakdown side of this cycle by suppressing the cells (osteoclasts) that dissolve old bone. When estrogen disappears at menopause, bone loss accelerates, and density can drop significantly within the first decade.
HRT reverses this trajectory. In a 10-year follow-up study, women on HRT saw their spine bone mineral density increase by about 13% from baseline, while untreated women lost nearly 5% over the same period. At the forearm, bone mineral content dropped less than 1% in treated women compared to a 17.6% loss in untreated women. By the end of the study, treated women had roughly 20% more forearm bone mineral content than their untreated counterparts. These aren’t small differences: they translate directly into fracture risk.
The Timing Window for Heart Health
For years, the relationship between HRT and heart disease was confusing, largely because a major trial in the early 2000s (the Women’s Health Initiative) enrolled many women well past menopause and found increased cardiovascular risk. Later analysis revealed that age at the time of starting treatment changes the equation dramatically.
The “timing hypothesis” holds that HRT started within 10 years of menopause onset, or before age 60, can benefit the cardiovascular system, while starting later may increase risk. The biological explanation is straightforward: in younger women with healthy arteries, estrogen improves the function of blood vessel linings, slows the buildup of early plaques, and reduces smooth muscle overgrowth. In older women whose arteries already have established plaque, estrogen can destabilize those deposits, increase inflammation within them, and promote clotting.
When researchers re-analyzed the Women’s Health Initiative data by age group, the numbers told a strikingly different story. Women who started estrogen-only therapy within 10 years of menopause had a 41% lower risk of coronary heart disease compared to placebo. Those who started combined estrogen-plus-progestogen therapy in the same window showed a 24% trend toward lower risk. Meanwhile, women who began HRT more than 20 years after menopause, or at age 70 and older, saw increased coronary events. A separate long-term Danish study confirmed these findings, showing that HRT started in recently menopausal women reduced cardiovascular events and mortality over 16 years of follow-up.
Breast Cancer Risk in Context
Breast cancer risk depends heavily on which type of HRT you use and for how long. Recent data from the National Institute of Environmental Health Sciences found that estrogen-only therapy was actually associated with a 14% reduction in breast cancer incidence compared to never using HRT. Combined estrogen-plus-progestogen therapy, by contrast, was linked to a 10% higher rate of breast cancer, rising to 18% higher for women who used it longer than two years.
In absolute terms, the numbers are closer together than the percentages might suggest. The cumulative risk of breast cancer before age 55 was estimated at about 4.5% for combined therapy users, 4.1% for women who never used HRT, and 3.6% for estrogen-only users. That’s a meaningful but modest difference, roughly one additional case per 250 women over the relevant time period. This is why the type of progestogen, the duration of use, and your individual risk factors all play into the decision.
What the First Months Look Like
When you start HRT, the most noticeable change for many women is the reduction in hot flashes and night sweats, typically within four to eight weeks. Some women experience breast tenderness, bloating, or light bleeding in the first few months as the body adjusts, particularly with combined therapy. These side effects generally settle within three to six months.
Improvements in sleep, mood, and vaginal dryness tend to follow a slightly longer timeline, often becoming apparent over two to three months. Bone density benefits accumulate gradually over years. Your prescriber will typically start at a low dose and adjust based on how you respond, since the goal is the lowest effective dose that controls your symptoms.